Author Archives: Gastroenterology Journal

Patients with inflammatory bowel disease (IBD) undergoing ERCP can be prone to having worse hospital outcomes due to certain comorbidities. There are limited studies that have examined the impact of cardiac arrhythmias on patients with IBD undergoing E… Continue reading →

Celiac disease (CeD) and inflammatory bowel disease (IBD) are autoimmune diseases of the bowel with similar clinical symptoms. This study aims to characterize the clinical course of both diseases in subjects with overlap of CeD and IBD (CeD+IBD) on a g… Continue reading →

Variation in clinical response to 5-aminosalicylic acid (5-ASA) has been attributed in part to its inactivation by gut microbes. Recently, in the Inflammatory Bowel Disease (IBD) Multi’omics Database (IBDMDB), a multicenter year-long cohort of 100+ par… Continue reading →

It has been estimated that about 25% of patients with inflammatory bowel disease (IBD) are diagnosed before the age of 18. Food insecurity, limited or lack of access to enough food, has been associated with poor outcomes in childhood health including m… Continue reading →

The Phoenix Children’s Hospital (PCH) Inflammatory Bowel Disease (IBD) Clinic provides care for nearly 500 patients. As a group, PCH is part of the ImproveCareNow (ICN) network—a collaboration of over 100 centers worldwide to improve IBD care. Patient … Continue reading →

Tofactinib is a JAK inhibitor that targets mainly JAK 1 and JAK3 approved to treat Ulcerative Colitis (UC) in 2018. The JAK inhibitor Upadacitinib (upa) was recently approved to treat UC in March 2022 and has increased selectivity for JAK1. The relativ… Continue reading →

This study sought to evaluate the impact of an evidence-based diet and lifestyle-factor intervention program on nutrition status, symptoms and quality of life of patients with IBD. Continue reading →

Surgery activates catabolic pathways that lead to loss of lean body mass and physical deconditioning, which can predispose to complications and delayed healing. Prehabilitation addresses modifiable risk factors, provides nutrition and functional status… Continue reading →

There is concern for the lack of data regarding the efficacy and negative effects of ergogenic aids (sport supplements) in patients with Inflammatory Bowel Disease (IBD). This is a prospective research project designed to determine which ergogenic aids… Continue reading →

There are limited data regarding fibrosis progression in biopsy-proven nonalcoholic fatty liver disease (NAFLD), between people with type 2 diabetes mellitus (T2DM) versus people without T2DM. We assessed the time to fibrosis progression in people with… Continue reading →